Predicted protein targets (top 6)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ACE | P12821 | 4/20 | 0.60 |
| ▸ | ECE1 | P42892 | 9/20 | 0.53 |
| ▸ | ITGB2 | P05107 | 1/20 | 0.51 |
| ▸ | ICAM1 | P05362 | 1/20 | 0.51 |
| ▸ | ITGAL | P20701 | 1/20 | 0.51 |
| ▸ | ALOX15 | P16050 | 1/20 | 0.50 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5963673 | 0.90 | ACE (0.48) | ACE | |
| SCHEMBL5964512 | 0.80 | ACE (0.52) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL5964517 | 0.80 | ACE (0.52) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL5963440 | 0.78 | ACE (0.42) | ACE | |
| SCHEMBL5253098 | 0.77 | ACE (0.70) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL10174744 | 0.77 | ACE (0.70) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL5253093 | 0.77 | ACE (0.70) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL19951595 | 0.76 | ACE (0.69) | ACEECE1ITGB2ICAM1ITGAL | |
| SCHEMBL3362555 | 0.76 | PPARA (0.46) | ACE | |
| SCHEMBL8466953 | 0.76 | ACE (0.82) | ACEECE1ITGB2ICAM1ITGAL |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | FINK CYNTHIA A | 2006-08-31 | — | — | US | disclosed |
| US-7071169-B2 | Pyrane derivatives as both ACE-and NEP-inhibitors | NOVARTIS AG (CH) | 2006-07-04 | — | — | US | disclosed |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | FINK CYNTHIA ANNE (US) | 2004-12-30 | — | — | US | disclosed |
| EP-1430045-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP-INHIBITORS | Novartis AG (CH) | 2004-06-23 | — | — | EP | disclosed |
| WO-2003027091-A1 | PYRANE DERIVATIVES AS BOTH ACE- AND NEP- INHIBITORS | NOVARTIS AG (CH) | 2003-04-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20060194742-A1 | Pyrane derivatives as both ACE- and NEP-inhibitors | ECE1, ECE2, AGTR1 | ACE 4/4885ECE1 1/4885ITGB2 4808/4885 |
| US-20040266698-A1 | Pyrane derivatives as both ace-and nep-inhibitors | ECE1, AGTR1, ACE | ACE 3/4885ECE1 1/4885ITGB2 4736/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.